Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024559 | 1.00 | DPP4 (0.46) | DPP4DRD2DRD3RORCFUCA1 | |
| SCHEMBL3024562 | 1.00 | DPP4 (0.46) | DPP4DRD2DRD3RORCFUCA1 | |
| SCHEMBL8065470 | 0.89 | SIGMAR1 (0.44) | DPP4DRD2DRD3SIGMAR1CCR5 | |
| SCHEMBL3033885 | 0.89 | SIGMAR1 (0.44) | DPP4DRD2DRD3SIGMAR1CCR5 | |
| SCHEMBL3020333 | 0.89 | SIGMAR1 (0.44) | DPP4DRD2DRD3SIGMAR1CCR5 | |
| SCHEMBL3020328 | 0.89 | SIGMAR1 (0.44) | DPP4DRD2DRD3SIGMAR1CCR5 | |
| SCHEMBL3033888 | 0.89 | SIGMAR1 (0.44) | DPP4DRD2DRD3SIGMAR1CCR5 | |
| SCHEMBL3028885 | 0.89 | DPP4 (0.45) | DPP4DRD2DRD3RORCFUCA1 | |
| SCHEMBL3028877 | 0.89 | DPP4 (0.45) | DPP4DRD2DRD3RORCFUCA1 | |
| SCHEMBL3028880 | 0.89 | DPP4 (0.45) | DPP4DRD2DRD3RORCFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | DPP4 903/4885DRD2 30/4885DRD3 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.